AI ASSISTANT
Ask DrugCentral
Explore drug information in your own words.
Type a question in the search bar above to get started. Each question is answered independently.
AI can make mistakes. Verify answers against the original sources before relying on them.
alitretinoin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| retinol derivatives | 3862 | 5300-03-8 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A retinoid that is used for the treatment of chronic hand ECZEMA unresponsive to topical CORTICOSTEROIDS. It is also used to treat cutaneous lesions associated with AIDS-related KAPOSI SARCOMA.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 20 | mg | O |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 0.33 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| azlogd74 | LogD at pH 7.4 | 3.436 | High | 1 | |
| caco2-efflux | Caco-2 efflux ratio (BA/AB) | 1.897 | High | 1 | |
| caco2-intrinsic-papp | Caco-2 intrinsic apparent permeability | 8.670 | 10^-6 cm/s | High | 1 |
| dh-clint | Dog hepatocyte intrinsic clearance | 37.068 | uL/min/10^6 cells | High | 1 |
| dppb | Dog plasma protein binding (% unbound) | 0.130 | % | High | 1 |
| fcs-ppb | Fetal calf serum protein binding (% unbound) | 0.270 | % | High | 1 |
| herg | hERG pIC50 | 4.709 | pIC50 | High | 1 |
| hh-clint | Human hepatocyte intrinsic clearance | 47.424 | uL/min/10^6 cells | High | 1 |
| hlm-clint | Human liver microsomal intrinsic clearance | 11.722 | uL/min/mg protein | High | 1 |
| hppb | Human plasma protein binding (% unbound) | 0.370 | % | High | 1 |
| kinase-safety-class | ACVR2A,ACVR2B,AURKA,AXL,BRAF,BTK,CAMK2D,CDK5,CDK9,DYRK1B,EGFR,EIF2AK3,ERBB2,GRK2,GSK3B,IKBKB,ITK,MAP2K6,MAP3K7,MAPK7,MAPKAPK2,PDK1,PDK2,PDK4,PIK3CB,PRKDC,STK33,SYK,TEK,TGFBR1 | 30 | |||
| kinase-selectivity-class | ACVR2B,AXL,BRAF,EIF2AK3,EPHB4,GRK2,MAP2K6,MAPK7,STK33,TEK,TTK | 11 | |||
| mdck-mdr1-efflux | MDCK-MDR1 efflux ratio | 1.722 | High | 1 | |
| mh-clint | Mouse hepatocyte intrinsic clearance | 44.157 | High | 1 | |
| mppb | Mouse plasma protein binding (% unbound) | 0.150 | High | 1 | |
| nih-mdck-mdr1-efflux | NIH MDCK-MDR1 efflux ratio | 3.622 | High | 1 | |
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 | |||
| pppb | Pig plasma protein binding (% unbound) | 0.110 | % | High | 1 |
| rh-clint | Rat hepatocyte intrinsic clearance | 26.915 | uL/min/10^6 cells | High | 1 |
| rh-fuinc | Rat hepatocyte fraction unbound in incubation | 5.680 | % | High | 1 |
| rppb | Rat plasma protein binding (% unbound) | 0.120 | % | High | 1 |
| solubility-dd | Solubility at pH 7.4 in DMSO | 80.724 | uM | High | 1 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Feb. 2, 1999 | FDA | EISAI INC |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Mandibular mass | 54.96 | 48.60 | 7 | 472 | 184 | 90627784 |
| Diverticulum oesophageal | 54.64 | 48.60 | 7 | 472 | 193 | 90627775 |
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Diverticulum oesophageal | 54.61 | 51.05 | 7 | 544 | 206 | 110588542 |
| Mandibular mass | 53.68 | 51.05 | 7 | 544 | 236 | 110588512 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | D11AH04 | DERMATOLOGICALS OTHER DERMATOLOGICAL PREPARATIONS OTHER DERMATOLOGICAL PREPARATIONS Agents for dermatitis, excluding corticosteroids |
| ATC | L01XF02 | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS OTHER ANTINEOPLASTIC AGENTS Retinoids for cancer treatment |
| FDA CS | M0018962 | Retinoids |
| MeSH PA | D000970 | Antineoplastic Agents |
| MeSH PA | D003879 | Dermatologic Agents |
| FDA EPC | N0000175607 | Retinoid |
| CHEBI has role | CHEBI:25212 | metabolite |
| CHEBI has role | CHEBI:35610 | antineoplastic agent |
| CHEBI has role | CHEBI:50176 | keratolytic drug |
| CHEBI has role | CHEBI:50177 | dermatologic drug |
| CHEBI has role | CHEBI:50748 | antipsoriatic |
| CHEBI has role | CHEBI:63794 | retinoid X receptor agonist |
Related Drugs by ATC class:
D11AH Agents for dermatitis, excluding corticosteroids 11 drugs
L01XF Retinoids for cancer treatment 2 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Kaposi's Sarcoma Skin Lesions | indication | ||
| Mycosis fungoides | contraindication | 118618005 | |
| Pregnancy, function | contraindication | 289908002 | |
| Breastfeeding (mother) | contraindication | 413712001 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 4.17 | acidic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Retinoic acid receptor alpha | Nuclear hormone receptor | AGONIST | EC50 | 6.52 | WOMBAT-PK | CHEMBL | |||
| Retinoic acid receptor RXR-alpha | Nuclear hormone receptor | AGONIST | EC50 | 6.50 | WOMBAT-PK | CHEMBL | |||
| Retinoic acid receptor RXR-beta | Nuclear hormone receptor | AGONIST | EC50 | 6.70 | WOMBAT-PK | CHEMBL | |||
| Retinoic acid receptor RXR-gamma | Nuclear hormone receptor | AGONIST | EC50 | 6.66 | WOMBAT-PK | CHEMBL | |||
| Retinoic acid receptor beta | Nuclear hormone receptor | AGONIST | EC50 | 7.30 | WOMBAT-PK | CHEMBL | |||
| Retinoic acid receptor gamma | Nuclear hormone receptor | AGONIST | EC50 | 7.13 | WOMBAT-PK | CHEMBL | |||
| Nuclear receptor ROR-gamma | Nuclear hormone receptor | EC50 | 4.85 | CHEMBL | |||||
| Nuclear receptor subfamily 4 group A member 1 | Nuclear other | Kd | 6.09 | CHEMBL | |||||
| Oxysterols receptor LXR-beta | Nuclear other | EC50 | 5.76 | CHEMBL | |||||
| Oxysterols receptor LXR-alpha | Nuclear other | EC50 | 5.96 | CHEMBL | |||||
| Retinoic acid receptor RXR-beta | Transcription factor | Kd | 7.92 | CHEMBL | |||||
| Retinoic acid receptor RXR-gamma | Transcription factor | Kd | 8.40 | CHEMBL | |||||
| Retinoic acid receptor alpha | Transcription factor | Kd | 8.15 | CHEMBL | |||||
| Retinoic acid receptor RXR-alpha | Transcription factor | Kd | 7.49 | CHEMBL | |||||
| Retinoic acid receptor beta | Transcription factor | Kd | 8.15 | CHEMBL | |||||
| Retinoic acid receptor gamma | Transcription factor | Kd | 7.77 | CHEMBL | |||||
| Retinoic acid receptor RXR-alpha | Nuclear hormone receptor | EC50 | 6.96 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 4021155 | VUID |
| N0000148606 | NUI |
| D02815 | KEGG_DRUG |
| 4021155 | VANDF |
| C0281666 | UMLSCUI |
| CHEBI:50648 | CHEBI |
| CHEMBL705 | ChEMBL_ID |
| DB00523 | DRUGBANK_ID |
| D000077556 | MESH_DESCRIPTOR_UI |
| 449171 | PUBCHEM_CID |
| 2645 | IUPHAR_LIGAND_ID |
| 7781 | INN_ID |
| 1UA8E65KDZ | UNII |
| 219098 | RXNORM |
| 14093 | MMSL |
| 7957 | MMSL |
| 007747 | NDDF |
| 116086005 | SNOMEDCT_US |
| 409488005 | SNOMEDCT_US |
| 9CR | PDB_CHEM_ID |
| 1UA8E65KDZ | INXIGHT DRUGS |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| PANRETIN | Human Prescription Drug Label | 1 | 59212-601 | GEL | 60 mg | TOPICAL | NDA | 24 sections |
| CLINDAMYCIN 1% / NIACINAMIDE 4% / TRETINOIN 0.05% | HUMAN PRESCRIPTION DRUG LABEL | 3 | 72934-2054 | CREAM | 0.05 g | TOPICAL | unapproved drug other | 4 sections |